Corvus Pharmaceuticals, Inc. (CRVS) Balance Sheet
As of 2026-06-30 (10-Q), Corvus Pharmaceuticals, Inc. (CRVS) reported total assets of $239.3M, total liabilities of $13.9M and shareholders' equity of $225.3M, according to EquiReason's reading of its SEC filings. Cash and equivalents: $18.9M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
CRVSCorvus Pharmaceuticals, Inc.Follow CRVS — free
—
Price chart with a free account
- Market cap
- 885.8M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 29 Oct, in 5 days
| Line | FY2016 Dec 16 | FY2017 Dec 17 | FY2018 Dec 18 | FY2019 Dec 19 | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | Latest Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 5.1 | 45.1 | 39.2 | 5.2 | 16.5 | 63.5 | 13.2 | 12.6 | 8.7 | 4.6 | 18.9 | |
| Short-term investments | — | — | — | — | — | — | — | — | 43.2 | 52.2 | 196.3 | |
| Receivables | — | — | — | — | — | — | 0.6 | 0.0 | 0.1 | 0.0 | 0.0 | |
| Current assets | 136.0 | 91.2 | 115.6 | 79.3 | 45.3 | 71.3 | 43.7 | 28.0 | 54.4 | 58.2 | 221.0 | |
| Total assets | 140.2 | 94.8 | 118.2 | 83.6 | 85.5 | 109.5 | 68.2 | 45.6 | 68.9 | 71.1 | 239.3 | |
| Current liabilities | 5.9 | 9.0 | 7.0 | 10.2 | 12.1 | 9.7 | 10.8 | 6.9 | 35.4 | 9.4 | 13.7 | |
| Total liabilities | 7.3 | 9.9 | 7.9 | 12.5 | 13.4 | 12.3 | 12.1 | 6.9 | 36.3 | 9.9 | 13.9 | |
| Shareholders' equity | 132.8 | 84.8 | 110.3 | 71.1 | 72.1 | 97.2 | 56.1 | 38.7 | 32.6 | 61.2 | 225.3 |
USD millions · SEC XBRL
Corvus Pharmaceuticals, Inc. — questions
- How much cash does Corvus Pharmaceuticals, Inc. have?
- $18.9M in cash and cash equivalents as of 2026-06-30.
- What are Corvus Pharmaceuticals, Inc.'s total assets?
- $239.3M as of 2026-06-30.
- What is Corvus Pharmaceuticals, Inc.'s shareholders' equity?
- $225.3M as of 2026-06-30.
Every figure on this page comes from Corvus Pharmaceuticals, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.